Ultragenyx Pharmaceutical Inc. (RARE) Social Stream
ULTRAGENYX PHARMACEUTICAL INC (RARE) Price Targets From Analysts
Use the tables below to see what analysts covering ULTRAGENYX PHARMACEUTICAL INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-05 | 16 | $185 | $73 | $146.2 | $49.61 | 194.7% |
| 2022-01-11 | 16 | $185 | $73 | $143.933 | $49.61 | 190.13% |
| 2022-01-25 | 16 | $185 | $73 | $143 | $49.61 | 188.25% |
| 2022-01-26 | 16 | $185 | $73 | $142.4 | $49.61 | 187.04% |
| 2022-01-31 | 16 | $185 | $73 | $140 | $49.61 | 182.2% |
| 2022-02-11 | 16 | $185 | $73 | $140 | $49.61 | 182.2% |
| 2022-02-14 | 15 | $185 | $73 | $139.466 | $49.61 | 181.12% |
| 2022-04-26 | 15 | $186 | $73 | $139.533 | $49.61 | 181.26% |
| 2022-04-28 | 15 | $186 | $73 | $139.666 | $49.61 | 181.53% |
| 2022-05-05 | 15 | $186 | $73 | $138.461 | $49.61 | 179.1% |
| 2022-05-09 | 13 | $186 | $71 | $129.538 | $49.61 | 161.11% |
| 2022-05-18 | 13 | $186 | $71 | $126.846 | $49.61 | 155.69% |
| 2022-05-24 | 14 | $186 | $71 | $125 | $49.61 | 151.97% |
| 2022-07-28 | 13 | $185 | $70 | $121.5 | $49.61 | 144.91% |
| 2022-08-01 | 14 | $185 | $60 | $111.571 | $49.61 | 124.9% |
| 2022-08-02 | 14 | $185 | $60 | $112.666 | $49.61 | 127.1% |
| 2022-08-13 | 14 | $185 | $60 | $117.266 | $49.61 | 136.38% |
| 2022-09-17 | 13 | $185 | $60 | $117.266 | $49.61 | 136.38% |
| 2022-10-12 | 11 | $185 | $60 | $117.266 | $49.61 | 136.38% |
| 2022-10-21 | 13 | $185 | $50 | $112 | $49.61 | 125.76% |
| 2022-10-25 | 13 | $185 | $50 | $111.5 | $49.61 | 124.75% |
| 2022-11-03 | 14 | $164 | $49 | $102.312 | $49.61 | 106.23% |
| 2022-11-04 | 14 | $143 | $49 | $101 | $49.61 | 103.59% |
| 2022-12-07 | 14 | $143 | $49 | $98.125 | $49.61 | 97.79% |
| 2022-12-13 | 14 | $143 | $49 | $94.937 | $49.61 | 91.37% |
| 2023-01-13 | 15 | $143 | $49 | $94.176 | $49.61 | 89.83% |
| 2023-01-26 | 15 | $143 | $48 | $94.117 | $49.61 | 89.71% |
| 2023-01-27 | 15 | $143 | $48 | $92.823 | $49.61 | 87.11% |
| 2023-02-01 | 15 | $143 | $48 | $92.823 | $49.61 | 87.11% |
| 2023-02-16 | 15 | $143 | $48 | $92.529 | $49.61 | 86.51% |
| 2023-02-21 | 15 | $142 | $47 | $91.823 | $49.61 | 85.09% |
| 2023-04-17 | 15 | $142 | $47 | $91.588 | $49.61 | 84.62% |
| 2023-04-24 | 15 | $142 | $47 | $91.47 | $49.61 | 84.38% |
| 2023-05-05 | 16 | $142 | $47 | $92.722 | $49.61 | 86.9% |
| 2023-05-08 | 16 | $142 | $47 | $92.388 | $49.61 | 86.23% |
| 2023-05-11 | 16 | $142 | $48 | $91.777 | $49.61 | 85% |
| 2023-05-23 | 16 | $142 | $48 | $92 | $49.61 | 85.45% |
The Trend in the Analyst Price Target
Over the past 16 months, RARE's average price target has gone down $48.
Over the past 43 weeks, RARE's average upside potential has been 129.5%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-07-28 | 13 | 185 | 70 | 121.500 | 51.88 | 134.19% |
| 2022-12-13 | 15 | 143 | 49 | 94.937 | 44.93 | 111.3% |
| 2023-01-08 | 15 | 143 | 49 | 94.176 | 46.66 | 101.83% |
| 2023-02-03 | 15 | 143 | 48 | 92.529 | 45.73 | 102.34% |
| 2023-04-17 | 15 | 142 | 47 | 91.588 | 40.75 | 124.76% |
RARE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.38 | 13 | 0 | 3 | 0 | 0 | 16 |
The Trend in the Broker Recommendations
Over the past 21 months, RARE's average broker recommendation rating improved by 0.68.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RARE as an investment opportunity.
- To contextualize these metrics, consider that out of stocks in the large market cap category, ULTRAGENYX PHARMACEUTICAL INC's upside potential (average analyst target price relative to current price) is higher than 3626.56% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, ULTRAGENYX PHARMACEUTICAL INC's number of analysts covering the stock is higher than 3618.58% of them.
- In the context of stocks in the large market cap category, ULTRAGENYX PHARMACEUTICAL INC's variance in analysts' estimates is lower than -3498.54% of them.
- In the context of Pharmaceutical Products stocks, ULTRAGENYX PHARMACEUTICAL INC's average analyst price target is higher than 3563.59% of them.
Stocks similar to ULTRAGENYX PHARMACEUTICAL INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ALKS, ALNY, and UTHR.
View All Top Stocks by Price Target
Is RARE a Buy, Hold or Sell? See the POWR Ratings now!